Emanuele Valeriani1, Alessandro Squizzato2, Andrea Gallo2, Ettore Porreca1, Jean-Louis Vincent3, Toshiaki Iba4, Akiyoshi Hagiwara5, Marcello Di Nisio6,7. 1. Department of Medical, Oral and Biotechnological Sciences, "G. D'Annunzio" University, Chieti, Italy. 2. Department of Medicine and Surgery, Research Centre on Thromboembolic Diseases and Antithrombotic Therapies, University of Insubria, Varese and Como, Italy. 3. Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. 4. Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan. 5. Department of Emergency Medicine and Critical Care, National Center for Global Health and Medicine, Tokyo, Japan. 6. Department of Medicine and Ageing Sciences, "G. D'Annunzio" University, Chieti-Pescara, Italy. 7. Department of Vascular Medicine, Academic Medical Centre, Amsterdam, the Netherlands.
Abstract
BACKGROUND: The efficacy and safety of recombinant human soluble thrombomodulin (rhsTM) have not been definitively proven. The effects may depend on the presence of sepsis-associated coagulopathy (SAC). OBJECTIVES: The aim of this systematic review and meta-analysis was to evaluate the efficacy and safety of rhsTM in patients with SAC defined by high international normalized ratio and low platelet count. PATIENTS/ METHODS: EMBASE, MEDLINE, CENTRAL, and clinicaltrial.gov were searched for randomized controlled trials (RCTs) comparing rhsTM with placebo or no treatment in patients with sepsis. The efficacy outcome was 28-day mortality, and the safety outcome was major bleeding. RESULTS: We included 3 RCTs with a total of 1633 patients. Twenty-eight-day mortality was higher in patients with SAC compared with those without SAC (risk ratio [RR] 1.32; 95% confidence intervals [CI], 1.06-1.64). rhsTM was associated with significantly lower 28-day mortality compared with placebo or no treatment in patients with SAC (RR 0.80; 95% CI, 0.65-0.98), but not in those without SAC (RR 1.17; 95% CI, 0.82-1.67) nor in the whole study population (RR 0.88; 95% CI, 0.74-1.04). There was no significant difference in major bleeding between rhsTM and controls in the whole population (RR 1.25; 95% CI, 0.80-1.96), patients with SAC (RR 0.94; 95% CI, 0.45-1.95), and those without SAC (RR 2.26; 95% CI, 0.95-5.35). CONCLUSIONS: In patients with sepsis, SAC is associated with higher 28-day mortality. The administration of rhsTM reduced 28-day mortality in patients with SAC, but not in those without SAC.
BACKGROUND: The efficacy and safety of recombinant human soluble thrombomodulin (rhsTM) have not been definitively proven. The effects may depend on the presence of sepsis-associated coagulopathy (SAC). OBJECTIVES: The aim of this systematic review and meta-analysis was to evaluate the efficacy and safety of rhsTM in patients with SAC defined by high international normalized ratio and low platelet count. PATIENTS/ METHODS: EMBASE, MEDLINE, CENTRAL, and clinicaltrial.gov were searched for randomized controlled trials (RCTs) comparing rhsTM with placebo or no treatment in patients with sepsis. The efficacy outcome was 28-day mortality, and the safety outcome was major bleeding. RESULTS: We included 3 RCTs with a total of 1633 patients. Twenty-eight-day mortality was higher in patients with SAC compared with those without SAC (risk ratio [RR] 1.32; 95% confidence intervals [CI], 1.06-1.64). rhsTM was associated with significantly lower 28-day mortality compared with placebo or no treatment in patients with SAC (RR 0.80; 95% CI, 0.65-0.98), but not in those without SAC (RR 1.17; 95% CI, 0.82-1.67) nor in the whole study population (RR 0.88; 95% CI, 0.74-1.04). There was no significant difference in major bleeding between rhsTM and controls in the whole population (RR 1.25; 95% CI, 0.80-1.96), patients with SAC (RR 0.94; 95% CI, 0.45-1.95), and those without SAC (RR 2.26; 95% CI, 0.95-5.35). CONCLUSIONS: In patients with sepsis, SAC is associated with higher 28-day mortality. The administration of rhsTM reduced 28-day mortality in patients with SAC, but not in those without SAC.
Authors: Behnood Bikdeli; Mahesh V Madhavan; Aakriti Gupta; David Jimenez; John R Burton; Caroline Der Nigoghossian; Taylor Chuich; Shayan Nabavi Nouri; Isaac Dreyfus; Elissa Driggin; Sanjum Sethi; Kartik Sehgal; Saurav Chatterjee; Walter Ageno; Mohammad Madjid; Yutao Guo; Liang V Tang; Yu Hu; Laurent Bertoletti; Jay Giri; Mary Cushman; Isabelle Quéré; Evangelos P Dimakakos; C Michael Gibson; Giuseppe Lippi; Emmanuel J Favaloro; Jawed Fareed; Alfonso J Tafur; Dominic P Francese; Jaya Batra; Anna Falanga; Kevin J Clerkin; Nir Uriel; Ajay Kirtane; Claire McLintock; Beverley J Hunt; Alex C Spyropoulos; Geoffrey D Barnes; John W Eikelboom; Ido Weinberg; Sam Schulman; Marc Carrier; Gregory Piazza; Joshua A Beckman; Martin B Leon; Gregg W Stone; Stephan Rosenkranz; Samuel Z Goldhaber; Sahil A Parikh; Manuel Monreal; Harlan M Krumholz; Stavros V Konstantinides; Jeffrey I Weitz; Gregory Y H Lip Journal: Thromb Haemost Date: 2020-05-30 Impact factor: 5.249
Authors: Pedro Castro; Marta Palomo; Ana Belen Moreno-Castaño; Sara Fernández; Sergi Torramadé-Moix; Georgina Pascual; Julia Martinez-Sanchez; Edward Richardson; Adrián Téllez; Josep M Nicolas; Enric Carreras; Paul G Richardson; Juan José Badimon; Gines Escolar; Maribel Diaz-Ricart Journal: Cardiovasc Drugs Ther Date: 2021-06-07 Impact factor: 3.947